Business, energy, technology, markets and global industry news from Business News Today

Telix Pharmaceuticals Limited

PharmaDeviceNews Telix Pharmaceuticals Limited
Representative image: Telix Pharmaceuticals’ PSMA-PET imaging collaborations with EDAP TMS and Profound Medical highlight how advanced prostate cancer scans could support minimally invasive treatment planning, focal ablation decisions and post-treatment monitoring in next-generation urology workflows.
Medical Devices & Diagnostics

Why Telix is taking PSMA-PET deeper into minimally invasive prostate cancer treatment

Prostate ablation is getting more precise. Telix wants PSMA-PET to become the imaging layer that helps clinicians decide where to treat.

Read More
Representative image: Advanced brain PET imaging for glioma assessment, reflecting how Telix Pharmaceuticals Limited’s TLX101-Px could expand standardized FET-PET access for brain cancer diagnosis and treatment decision-making in Europe.
Medical Devices & Diagnostics

Telix just moved a brain cancer imaging asset into Europe’s regulatory fast lane

Europe needs standardized glioma PET imaging. Telix TLX101-Px now tests whether regulators and payers are ready for FET-PET access.

Read More
Pharma & Biotech

What Plus Therapeutics Inc.’s SpectronRx partnership reveals about radiopharmaceutical manufacturing readiness

Discover how Plus Therapeutics Inc. is scaling REYOBIQ manufacturing for pivotal trials and what it means for radiopharmaceutical innovation.

Read More
Pharma & Biotech

How Telix Pharmaceuticals Limited may be building a stronger neuro-oncology diagnostics franchise

Telix Pharmaceuticals Limited’s TLX101-Px NDA has been accepted by the FDA. Discover what this means for glioma imaging and the September decision.

Read More